Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
More articles/Ad
More articles/Ad
More articles
-
Simcere Pharmaceutical Group has bagged HK$3.57bn ($460.6m) from its IPO, after sealing the offer at the top end of the price guidance, according to a source familiar with the deal. -
With 2020 already a busy year for emerging market bond restructuring, the head of the IMF has publicly urged countries to act decisively and early if they face a debt crisis that looks more likely after the G20 did not say it would address countries’ mounting burdens.
-
India’s economic future is on shaky ground, after the Covid-19 pandemic dealt a blow to the country’s already faltering growth. The impact of the fallout is likely to be felt for years to come — unless the government quickly changes tack.
-
Synairgen, the UK biopharmaceuticals company, has raised £80m from investors to fund the next stage of clinical trials for a treatment designed to alleviate the respiratory symptoms of Covid-19.
-
Oil prices, which are key to the public finances of many MENA states, have recovered somewhat since their abrupt slump earlier this year but experts are not optimistic they will regain the levels seen at the start of 2020
-
Aedifica, the Belgian healthcare real estate investment company, which owns a portfolio of care homes, has launched a €459m rights issue to fund an acquisition and to grow its development pipeline. Sources close to the deal are confident that the cash call will be popular given investor demand for exposure to speciality real estate businesses.
